PaxMedica

PaxMedica is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for unmet needs in neurodevelopmental disorders. The company is advancing PAX-101 for applications in autism spectrum disorder (ASD), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), long COVID syndrome, and fragile X-associated tremor/ataxia syndrome (FXTAS). Despite the prevalence of ASD in many communities, there are currently no FDA-approved treatments targeting its core symptoms. PaxMedica’s most advanced clinical candidate, PAX-101, is currently being evaluated in clinical trials for the treatment of children with ASD.